Gangwal Healthcare DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News

Gangwal Plot N-5 In Boisar, Palghar, India Receives Excipact GMP Certification

10 Jul 2023

// PRESS RELEASE

The nutrition industry is fast catching up with pharma by way of regulations, quality and clinical trials

25 Jul 2022

// ET HEALTH

Gangwal Healthcare to set up unit for manufacturing nutraceuticals

29 Jan 2022

// THE HINDU

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

CPHI Middle east

Not Confirmed

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

4 CORPORATE CONTENT #SupplierSpotlight, 1 DATA COMPILATION #PharmaFlow, 3 NEWS #PharmaBuzz

media
4 CORPORATE CONTENT #SupplierSpotlight
1 DATA COMPILATION #PharmaFlow
3 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

13 All APIs, 2 USDMF, 3 EU WC, 12 Listed APIs

13 All APIs
2 USDMF
3 EU WC
12 Listed APIs

FINISHED DOSAGE FORMULATIONS

16 FDF Dossiers, 16 Listed Dossiers

16 FDF Dossiers
16 Listed Dossiers

KEY PRODUCTS

Isoxsuprine Hydrochloride, Salmeterol Xinafoate

Isoxsuprine Hydrochloride
Salmeterol Xinafoate

SERVICES

Drug Product Manufacturing

pharmaServices
Drug Product Manufacturing
- 1 Dietary Supplement (Nutraceutical)

EXCIPIENTS

16 All Excipients, 16 USDMF, 22 Listed Products

excipientPortfolio
16 All Excipients
16 USDMF
22 Listed Products

KEY EXCIPIENTS

Ristar™, Tyloxapol, Complexol HP®, Complexol B®, STARLOSE®, ProBlend®, DiCOM-DC® PL009 P60, DiCOM-DC® SP204, DiCOM-DC® SR300, DiCOM-DC® S604, DiCOM-DC® S-Star, Innogel 9000/9500, Lactose DC, Microlose™ M60 P60

Ristar™
Tyloxapol
Complexol HP®
Complexol B®
STARLOSE®
ProBlend®
DiCOM-DC® PL009 P60
DiCOM-DC® SP204
DiCOM-DC® SR300
DiCOM-DC® S604
DiCOM-DC® S-Star
Innogel 9000/9500
Lactose DC
Microlose™ M60 P60

EXCIPIENTS BY INGREDIENTS

Microcrystalline Cellulose, Maize Starch, Lactose Monohydrate, Sodium Starch Glycolate, Corn Starch, Pregelatinized, Sucralose, Silicon Dioxide, Acesulfame Potassium, Hydroxypropyl Betacyclodextrin, Talc, EthylCellulose, Neotame, Croscarmellose Sodium, Magnesium Oxide Excipient, Calcium Carbonate Excipient, Hydroxypropyl Cellulose, Tyloxapol, Beta-Cyclodextrin, Polyvinyl pyrrolidone, Sodium Stearyl Fumarate, Sorbitol, Rice Starch, Magnesium Stearate, Hydroxypropyl Methylcellulose

EXCIPIENTS BY APPLICATIONS

Direct Compression, Fillers, Diluents & Binders, Co-Processed Excipients, Disintegrants & Superdisintegrants, Taste Masking, Thickeners and Stabilizers, Controlled & Modified Release, Solubilizers, Lubricants & Glidants, Film Formers & Plasticizers, Parenteral

excipientsByApplications
Direct Compression
Fillers, Diluents & Binders
Co-Processed Excipients
Disintegrants & Superdisintegrants
Taste Masking
Thickeners and Stabilizers
Controlled & Modified Release
Solubilizers
Lubricants & Glidants
Film Formers & Plasticizers
Parenteral

Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

About

Gangwal Healthcare – a solutions provider for Complex, Innovative & Cutting-edge technological formulations!
The building of a "best-in-class" solution provider starts with understanding the complexities of a customer's needs and identifying gaps. New technologies and Drug Delivery Systems are studied, and appropriate excipients are identified to resolve the problem. Working closely with our customers for over 35 years, Gangwal has made this possible due to a team of highly technical and marketing professionals with decades of experience in problem-solving.

CPHI Middle eastCPHI Middle east

Industry Trade Show

Not Confirmed

10-12 December, 2024

Riyadh Exhibition & Convention Center
Medlab Asia & Asia Hea...Medlab Asia & Asia Health

Industry Trade Show

Not Confirmed

24 November-17 July, 2025

Malaysia Trade & Exhibition Centre
Health 2.0 ConferenceHealth 2.0 Conference

Industry Trade Show

Not Confirmed

02-04 December, 2024

Dubai, UAE

CONTACT DETAILS

Click the arrow to open the dropdown

Country

India

Address

705, Quantum Tower, Rambagh Lane, Behind State Bank Of India, Malad (west), Mu...

Telephone

+91 2228888567

info@gangwalhealthcare.com

Website

https://gangwalhealthcare.com/

https://www.linkedin.com/company/gangwal-healthcare-pvt-ltd

YouTube

http://www.youtube.com/@Granules-IndiaLimited

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

Product List 2024

Open PDF

Upload

Corporate Presentation

Open PDF

Upload

Corporate Video

Customer Testimonials

DATA COMPILATION #PharmaFlow

Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards. Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio. Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients. The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.